key: cord-0835578-9a6gwx57
authors: Naderi, Nadereh; Rahimzadeh, Mahsa
title: Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
date: 2021-12-04
journal: Virology
DOI: 10.1016/j.virol.2021.11.006
sha: 85a00539c017c6c79906c78bfaad0b896756d34b
doc_id: 835578
cord_uid: 9a6gwx57

BACKGROUND: Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells, and has been proposed as a marker of COVID-19 and the severity of the disease. Here, we performed a meta-analysis to determine whether KL-6 could be used as a prognostic factor for severe COVID-19. METHODS: PubMed, Cochrane and Google Scholar were searched until April 20, 2021, and 7 studies were included. KL-6 was considered as the outcome and pooled in meta-analyses. RESULTS: All included studies compared KL-6 in severe and non-severe patients. Serum KL-6 was higher in severe COVID-19 patients compared to non-severe (n = 6; SMD = 1.25; 95% CI: 0.99–1.5; P < 0.001) and healthy controls (n = 4; SMD = 3.07; 95% CI: 1.36–4.8; P < 0.001). CONCLUSION: This data collection revealed the potential clinical significance of KL-6 as a non-expensive predictive biomarker in severe COVID-19 and for the categorization of COVID-19 clinical severity.

KL6.

Exclusion criteria were as follows:

1. Case reports or case series with less than ten subjects.

2. Reviews, meeting abstracts and guidelines.

3. Studies that were not peer-reviewed or their results were not clear and data could not be extracted.

Two independent authors screened titles, abstracts and full-text of all citations to identify the potentially eligible studies. The demographic data of the eligible studies including age, gender and sample size were extracted. The method of COVID-19 diagnoses, patients' classification, country or region of study population, type of study and method of KL-6 identification were also recorded. The methodological quality of the included studies evaluated by two authors independently using the NIH (national institutes of health) risk of bias check list for case-control and cross-sectional studies (https://www.nhlbi.nih.gov/healthtopics/study-quality-assessment-tools). Authors discussed in case of any disagreements. The total score for case-control studies was 12 and 9 for cross-sectional studies. Studies passed the quality assessment if they got the minimum score of 50%. Any dissension among researchers was resolved by final discussion to reach a consensus.

Extracted data were analyzed using the STATA software package (version 14.1, STATA Corp, College Station, TX). KL-6 serum levels were extracted as mean and standard deviation (SD) or median and interquartile range (IQR) in which data converted to mean and SD as described by Hozo et al. (Hozo, Djulbegovic et al. 2005) . Outcomes were presented as J o u r n a l P r e -p r o o f standardized mean differences (SMD) between severe and non-severe COVID-19 patients and severe and healthy control based on the patient's classification in the included studies.

Heterogeneity was assessed using Cochran's Q-test (Lipsey and Wilson 2001) . High degree heterogeneity was defined as I2> 25% and p ≥ 0.10 and a random-effects model was applied.

To identify how each study contributes to the overall analysis, a sensitivity analysis was performed as Patsopoulos et al. (Patsopoulos, Evangelou et al. 2008) . Since the number of included studies were limited, publication bias was evaluated for studies which compared severe and non-severe COVID-19 and funnel plot and Egger's statistical test were reported (P0.1 was considered as significant). A Random effect mete-regression was performed to assess heterogeneity.

The initial database search yielded 287 records,) 113 from PubMed and 174 from Google scholar, no records found from Cochrane). After duplicates were removed, a total of 77 records were screened for eligibility. 1 study was found by manually searching (Zeng, Di et al. 2020) .Of these, 1 meeting abstract, 2 not written in the English language, 40 not relevant, 2 reviews were excluded. The full text of 33 remained studies was assessed for eligibility and 12 case reports or case series (Horii, Kamada et al. 2020 , Inoue, Jinno et al. 2020 , Ito, Yokoyama et al. 2020 , Nakamura, Miyagi et al. 2020 , Scarpati 2020 , Shibata, Ishiguro et al. 2020 , Shimazu, Yoshiya et al. 2020 , Zeng, Chen et al. 2020 , Fukada, Kitagawa et al. 2021 , Sumimoto, Taniguchi et al. 2021 , Suzuki, Tanino et al. 2021 , Yamaya, Baba et al. 2021 , 2 studies that did not report the results clearly (Miyagami, Uehara et al. 2021 , Takeshita, Nishina et al. 2021 ), 3 studies that did not classify patients based on disease severity (Frix, Schoneveld et al. 2020 , Scotto, Pinchera et al. 2021 ) and 1 preprint study (Alimova, Sidhom et al. 2020) were excluded. Finally, 15 studies identified as relevant J o u r n a l P r e -p r o o f and entered the quality assessment (Awano, Inomata et al. 2020 , d'Alessandro, Bergantini et al. 2020 , d'Alessandro and Cameli 2020 , d'Alessandro, Cameli et al. 2020 , Frix, Schoneveld et al. 2020 , jp 2020 , Saito, KURONUMA et al. 2020 , Xue, Zheng et al. 2020 , Anai, Akaike et al. 2021 , Deng, Fan et al. 2021 , He, Lu et al. 2021 , Peng, Luo et al. 2021 , Scotto, Pinchera et al. 2021 . Ultimately, 7 studies (1 cross-sectional and 6 casecontrol studies) met the inclusion criteria of this systematic review (Awano, Inomata et al. 2020 , d'Alessandro, Cameli et al. 2020 , Saito, KURONUMA et al. 2020 , Deng, Fan et al. 2021 , He, Lu et al. 2021 (Table 1) . Table

Seven studies provided sufficient information to allow the comparison of the serum KL-6 levels between severe and non-severe patients (Awano, Inomata et al. 2020 , d'Alessandro, Cameli et al. 2020 , Saito, KURONUMA et al. 2020 , Deng, Fan et al. 2021 , He, Lu et al. 2021 . Four studies included sufficient data for the comparison of serum KL-6 levels between severe and control groups (d'Alessandro, Cameli et al. 2020 , Deng, Fan et al. 2021 , He, Lu et al. 2021 ). Three studies reported KL-6 serum level in non-severe and control groups (d'Alessandro, Cameli et al. 2020 , Deng, Fan et al. 2021 ). These studies did not include in meta-analyses because of the low sample size.

At first, data pooling was performed by both fixed and random effect models and if the heterogeneity was higher than 25%, the random effect was used. Data pooling with random effect model performed in 6 studies comparing serum KL-6 concentrations between severe and non-severe patients (Awano, Inomata et al. 2020 , d'Alessandro, Cameli et al. 2020 , Saito, KURONUMA et al. 2020 , Deng, Fan et al. 2021 . Results showed that the KL-6 concentration was higher in severe COVID-19 patients than non-severe patients (n=6; SMD= 1.25; 95% CI: 0.99-1.5; P<0.001). Q test results revealed that there was no heterogeneity between studies and both fixed-effect and random-effect analyses revealed the same results (n=6; I2=0.1%; P=0.4) (Fig.1A) .

Egger's tests revealed that publication bias was not significant (P=0.5). Funnel plot was shown in supplementary Fig.1. 

Four studies compared KL-6 serum levels between patients suffering from severe COVID-19 Peng, Luo et al. 2021) . Serum KL-6 was higher in severe COVID-19 patients than controls (n=4; SMD=3.07; 95% CI: 1.36-4.8; P<0.001). Cochran's Q-test revealed high heterogeneity (n=4; I2=95.2%; P<0.001) (Fig.1B) . To evaluate the source of heterogeneity, we used sensitivity analyses and each time 1 study was removed. After removing the He et al. study (He, Lu et al. 2021) , the between-study heterogeneity was reduced but still high (I2=85.4%, P=0.001). The KL-6 serum level in severe patients remained higher than control (n=3; SMD=1.86; 95% CI: 0.9-2.8; P=0.000). As can be seen from table 2, the mean ages of the study participants were different in the three studies (d' Alessandro, Cameli et al. 2020 , Deng, Fan et al. 2021 ) and therefore, the high heterogeneity in serum KL-6 levels in various studies might be attributed to the age. The mean age of the participants in control groups was lower than COVID-19 patients (60.93.9 years for severe and 53.19.9 years for control). Meta-regression was performed to identify if age was the sources of heterogeneity in the included studies. Conducting the meta-regression analysis based on age removed the heterogeneity (n=3; tau2=0; P>t = 0.0.86; I2res = 0.0%) (Fig.2 ).

Using a detailed search strategy and predetermined selection criteria and meta-analyses, we found that KL-6 levels in the serum of severe COVID-19 patients were significantly higher than non-severe patients and healthy controls (Fig.1A) . The results of this meta-analysis were consistent with those of previous studies indicating the prognostic value of KL-6 in severe COVID-19 (Nakamura, Miyagi et al. 2020 , Deng, Fan et al. 2021 . It has been shown that KL-6 plays essential role in pathophysiological processes. The increased levels of KL-6 in COVID-19 patients have been previously reported in different pulmonary diseases, including hypersensitivity pneumonia, idiopathic pulmonary fibrosis, pulmonary tuberculosis, radiation pneumonia, drug-induced ILDs, acute respiratory distress syndrome, lung cancer, and pulmonary sarcoidosis (Wu, Kuzmenko et al. 2003 , Sørensen, Hjelmborg et al. 2006 J o u r n a l P r e -p r o o f Doishita, Inokuma et al. 2011 , Ishikawa, Hattori et al. 2012 ). KL-6 levels reflecting the extent of damage and regeneration of type II pneumocytes can predict the risk of illness or death in subjects suffering from lung diseases such as polymyositis and dermatomyositis patients (Hu, Wu et al. 2019) . The studies indicated that increased levels of KL-6 in the epithelial lining fluid might arouse fibrotic processes in ILDs and is directly related with the pathogenic process of ILD and acute respiratory distress syndrome (ARDS ) (Bandoh, Fujita et al. 2000 , Fukaya, Oshima et al. 2000 , Yanaba, Hasegawa et al. 2003 , Sato, Callister et al. 2004 ).

The reason why increased serum KL-6 level can serve as a prognostic and predictive biomarker in COVID-19 patients has been unknown in detail but might be explained by KL-6 role as one of the key molecules involved in epithelial-mesenchymal interactions (Xu, Yan et al. 2013) .

Several studies showed that the injured AECs secreted large amounts of KL-6 which promoted lung fibrosis through multiple mechanisms including:

1-Attracting human fibroblasts which is enhanced by the addition of fibronectin (Hirasawa, ). 2-Triggering transforming growth factor-ß (TGF-ß) signaling has profibrotic and anti-apoptotic effects on lung fibroblasts (Zhong, Wu et al. 2020 ). 3-Upregulating the expression of collagen type I and III in a dose-dependent manner (Hirasawa, . 4-Inhibiting the fibroblasts from producing hepatocyte growth factor (HGF) (Xu, Yan et al. 2013) . HGF protects alveolar epithelial cells and increases the proliferation of these cells (Panos, Patel et al. 1996 , Shukla, Rose et al. 2009 ). In line with the above reasoning, Peng et al. study showed that serum KL-6 concentration in COVID-19 patients with signs of pulmonary fibrosis was higher than that in COVID-19 cases without fibrosis .

It seems logical that with exacerbation of COVID-19, a large amount of viral replication J o u r n a l P r e -p r o o f infiltration could destroy the alveolar epithelium and basement membrane leading to KL-6 secretion in patients BALF and blood (Xue, Zheng et al. 2020) which in the context of dysregulation of innate immune responses (Tahaghoghi-Hajghorbani, Zafari et al. 2020 ) and in cooperation with other chemoattractant for fibroblasts such as fibronectin (Sage, Farin et al. 1983 ), TGF-ß (Khalil, O'Connor et al. 1991) , epidermal growth factor (Grant, Khaw et al. 1992 , Raaberg, Nexo et al. 1992 , thrombin (Dawes, Gray et al. 1993 ) and collagens (Albini and Adelmann-Grill 1985, Bonner, Goodell et al. 1993 ) might contribute to the lung fibrosis.

This explanation is consistent with Xuo et al. study which showed that the levels of KL-6 reflected the damage of alveolar epithelium and were significantly correlated with the following indicators of disease severity: 1. Oxygenation index (PaO 2 /FiO 2 ), 2. the progress of lung lesion area ,and 3. changes of cytokine IL-6 (Xue, Zheng et al. 2020) .

However, these findings should be interpreted with caution since there are some limitations in our meta-analysis that should be considered. First, only a few studies were eligible for inclusion in the meta-analysis. Second, all of the studies were retrospective and observational. Third, subgroup analyses were hindered by lacking sufficient information about the association between KL-6 and disease outcome such as overall survival and need for ICU care and a cut-off value of serum KL-6. Further additional prospective or longitudinal studies focusing on the above information and extensive sample size studies are needed to be conducted for corroborating the association between KL-6 levels and COVID-19 unfavorable outcomes.

Interestingly, based upon previous research on the therapeutic effectiveness of the anti-KL-6 antibody in a mouse pulmonary fibrosis model, (Xu, Yang et al. 2013) , these findings could also raise the possibility of applying an anti-KL-6 antibody to prevent and treat pulmonary fibrosis following COVID-19 Infection. In summary, the current meta-analysis suggests that KL-6 as an auxiliary evaluation index of lung injury can be a non-expensive, rapid screening J o u r n a l P r e -p r o o f tool of COVID-19 severity which concomitant use with other potential COVID-19 biomarkers, including IL-6, troponin I, lactate dehydrogenase and lymphopenia can effectively improve clinical management and prevention of serious complications.

All relevant data are within the manuscript and its Supporting Information files. J o u r n a l P r e -p r o o f

Collagenolytic cleavage products of collagen type I as chemoattractants for human dermal fibroblasts

A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia

Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019

Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis

Prognostic bioindicators in severe COVID-19 patients

Chrysotile asbestos upregulates gene expression and production of alpha-receptors for platelet-derived growth factor (PDGF-AA) on rat lung fibroblasts

Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels

Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019

Thrombin stimulates fibroblast chemotaxis and replication

Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis

Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases

Could KL-6 levels in COVID-19 help to predict lung disease?

Presepsin as a predictive biomarker of severity in COVID-19: a case series

KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases

Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis

The Significance of KL-6 as Prognosis Monitoring Biomarker in Patients With Severe COVID-19 From Stabilized Stage Toward Convalescence

Rapidly progressive organizing pneumonia associated with COVID-19

Estimating the mean and variance from the median, range, and the size of a sample

Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis

Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD

Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases

Case Report: A Case of COVID-19 Pneumonia That Did Not Worsen and Was Relieved by Early Administration of Favipiravir and Ciclesonide

MUC1: the first respiratory mucin with an anti-inflammatory function

Increased production and immunohistochemical localization of transforming growth factor-b in idiopathic pulmonary fibrosis

Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis

Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma

Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease

Suppression of cellular aggregation by high levels of episialin

Delayed treatment of bacteremia during the COVID-19 pandemic

Serum KL-6 can distinguish between different phenotypes of severe COVID-19

New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6

Intratracheal administration of hepatocyte growth factor/scatter factor stimulates rat alveolar type II cell proliferation in vivo

Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation

Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019

Biomarkers associated with COVID-19 disease progression

Epidermal growth factor transcription, translation, and signal transduction by rat type II pneumocytes in culture

Granular pneumocytes in primary culture secrete several major components of the extracellular matrix

KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome

KL-6 levels in COVID-19

Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia

High incidence of false-positive results of IgG antibody against SARS-CoV-2 with rapid immunochromatographic antibody test due to human common cold coronavirus infection

The efficacy of combination therapies including antiviral drugs, methylprednisolone and daily proning in 20 patients with COVID

Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7

Genetic and environmental influences of surfactant protein D serum levels

Third international workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis

Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report

Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin

The role of dysregulated immune responses in COVID-19 pathogenesis

Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan

Detection of Serum KL-6 and SARS-CoV-2 Antibody in Patients with Coronavirus Disease 2019 and the Diagnostic Value in Severe Disease

Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability

KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation

Bleomycininduced pulmonary fibrosis is attenuated by an antibody against KL-6

Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China

Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Mild and moderate COVID-19 patients defined as non-severe

We thank Miss. Gisso Mehri for her valuable comments on this manuscript.

The authors declare that they had no competing interest.

The authors received funding from Hormozgan University of Medical Sciences, number: 990562.

For more information, visit www.prisma-statement.org. Records J o u r n a l P r e -p r o o f Table 3 . Criteria of the COVID-19 disease classification in the included studies.

Non-severe COVID-19 Moderate COVID-19Mild COVID-19Awano et al.Severe illness, patients who had a respiratory rate of >30 breaths per minute, SpO2 < 94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen < 300 mmHg, or lung infiltrates > 50%.Evidence of lower respiratory disease on clinical assessment or imaging and SpO2 > 94% on room air at sea level.Any of the various signs and symptoms of COVID-19 without shortness of breath, dyspnea, or abnormal chest imaging.

All patients underwent intubation and mechanical ventilation in the COVID intensive care unit (ICU).Patients (not requiring intubation) were hospitalized for pharmacological treatment and oxygen supplementation or noninvasive ventilation.

Not requiring intubation and invasive mechanical ventilation.

Patients were diagnosed as mild or severe/critical according to Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (seventh edition, General Office of National Health Commission).

Not mentioned.

Having dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 h.Having clinical symptoms, such as fever and cough, as well as CT imaging features of pneumonia.Having mild clinical symptoms without CT imaging features of pneumonia.

The disease is classified as severe if one of the following conditions is met: Respiratory distress, respiratory rate ≥30/min, Oxygen saturation on room air at rest ≤93%, Partial pressure of oxygen in arterial blood/FIO2 ≤300 mm Hg.J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f